Trial Profile
Phase 1 trial of ACT-017 for the treatment of Acute Ischemic Stroke
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jun 2020
Price :
$35
*
At a glance
- Drugs Glenzocimab (Primary)
- Indications Stroke
- Focus Adverse reactions; First in man
- 04 Jun 2020 Results published in the Journal of Clinical Pharmacology
- 06 Nov 2019 According to an Acticor Biotech media release, the company is looking forward to getting the results.
- 16 Mar 2019 Results presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics